Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …

It is 70 years since Noel Rose embarked on his pioneering studies that lead to the discovery
of autoimmune thyroiditis and the elucidation of Hashimoto's thyroiditis. This short review to …

Context Thyroid dysfunction occurs commonly following immune checkpoint inhibition. The
etiology of thyroid immune-related adverse events (irAEs) remains unclear and clinical …

Adrenal insufficiency (AI) is a condition characterized by an absolute or relative deficiency of
adrenal cortisol production. Primary AI (PAI) is rare and is caused by direct adrenal failure …

Immune checkpoint inhibitors (ICIs) have been changing the paradigm of cancer treatment.
However, immune-related adverse effects (irAEs) have also increased with the exponential …

Immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI)
therapy may vary substantially in their clinical presentation, including natural history …

Cancer immunotherapy, which leverages features of the immune system to target neoplastic
cells, has revolutionized the treatment of cancer. The use of these therapies has rapidly …

Background: Thyroid immune-related adverse events (IRAEs) have been reported more
frequently with programmed cell death protein-1 (PD-1) inhibitors than cytotoxic T …

The American Diabetes Association (ADA), European Association for the Study of Diabetes
(EASD), Joint British Diabetes Societies for Inpatient Care (JBDS), American Association of …

Immune checkpoint inhibitors (ICIs) block inhibitory molecules, such as cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or its …